Results 151 to 160 of about 5,159 (186)
Some of the next articles are maybe not open access.

Cerliponase Alfa for CLN2 Disease, a Promising Therapy

Expert Opinion on Orphan Drugs, 2020
Introduction: Neuronal ceroid lipofuscinosis type 2 (CLN2) is a rare, lysosomal storage disease that causes progressive neurodegeneration in children.
Nicolas J Abreu, Jonathan Pindrik
exaly   +2 more sources

Morphological studies on CLN2

European Journal of Paediatric Neurology, 2001
Electron microscopic, fluorescence microscopic, and immunohistochemical studies earlier performed on archival cerebral tissue from Max Bielchowsky's original three patients revealed curvilinear bodies rich in subunit C of mitochondrial ATP synthase (SCMAS). Recent progress in the elucidation of CLN2, i.e.
H H, Goebel   +3 more
openaire   +2 more sources

An essential function of Grr1 for the degradation of Cln2 is to act as a binding core that links Cln2 to Skp1

Journal of Cell Science, 1998
ABSTRACT In budding yeast, SCF complexes, composed of Skp1, Cdc53 and one of the F-box proteins, have been implicated in Cdc34-dependent ubiquitination. Grr1, which is required for degradation of G 1 cyclins Cln1 and Cln2 as well as for regulation of glucose repression, is an F-box protein and interacts with Skp1 through the F-box motif.
T, Kishi, F, Yamao
openaire   +2 more sources

Specific substrate for CLN2 proteaseltripeptidylpeptidaseI assay

European Journal of Paediatric Neurology, 2001
The classic late infantile neuronal ceroid lipofuscinosis (LINCL, CLN2) is a fatal neurodegenerative disorder that results from mutations in a gene encoding a lysosomal proteinase, known as CLN2 protease (CLN2p) or tripeptidyl peptidase I (TPP-I).
M A, Junaid, S S, Brooks, R K, Pullarkat
openaire   +2 more sources

Gene therapy for CLN2 disease

Science, 2020
Gene Therapy Late infantile Batten disease (CLN2 disease), a pediatric progressive brain disorder, is currently treated by infusion of human recombinant tripeptidyl peptidase 1 (TPP1) into the cerebrospinal fluid every other week, which slows but does not halt progression of the disease. Sondhi et al. sought an alternative treatment using gene therapy.
openaire   +1 more source

Mitochondrial abnormalities in CLN2 and CLN3 forms of batten disease

Molecular and Chemical Neuropathology, 1996
The storage of subunit c of mitochondrial ATP synthase, other hydrophobic peptides, and autofluorescent pigment in both late infantile (CLN2) and juvenile (CLN3) neuronal ceroid lipofuscinosis, but not in infantile (CLN1), has raised the question of abnormal mitochondrial function.
G, Dawson   +3 more
openaire   +2 more sources

Enzyme Replacement Therapy in CLN2-Associated Retinopathy

Klinische Monatsblätter für Augenheilkunde
AbstractNeuronal ceroid lipofuscinoses, also known as Batten disease, are comprised of a group of genetically heterogenous neurodegenerative conditions, characterized by dementia, epilepsy, motor deterioration, and blindness. The underlying pathology is a dysregulation of lysosomal catabolic protein metabolism, resulting in an accumulation of ...
Claudia Priglinger   +2 more
openaire   +2 more sources

Localization of proteins that are coordinately expressed with Cln2 during the cell cycle

Yeast, 2004
AbstractThe localization of proteins can give important clues about their function and help sort data from large‐scale proteomic screens. Forty‐five proteins were tagged with the GFP variant YFP. These proteins were chosen because they are encoded by genes that display strong cell cycle‐dependent expression that peaks in G1.
Bryan A, Sundin   +4 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy